Sprint Bioscience Dirección

Dirección controles de criterios 2/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Johan Emilsson

Chief Executive Officer (CEO)

n/a

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	1.3yrs
Participación del CEO	n/a
Permanencia media de la dirección	2.8yrs
Promedio de permanencia en la Junta Directiva	4.3yrs

Actualizaciones recientes de la dirección

Recent updates

Estimating The Fair Value Of Sprint Bioscience AB (publ) (STO:SPRINT)

Jun 12

A Look At The Intrinsic Value Of Sprint Bioscience AB (publ) (STO:SPRINT)

Feb 19

Is Sprint Bioscience (STO:SPRINT) In A Good Position To Deliver On Growth Plans?

Nov 19

CEO

Johan Emilsson (39 yo)

1.3yrs

Permanencia

Johan Emilsson is Chief Executive Officer of Sprint Bioscience AB (publ) from 2023. Johan Emilsson has broad experience in business development within the pharmaceutical industry and most recently from Fer...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Johan Emilsson	Chief Executive Officer	1.3yrs	sin datos	sin datos
Pär Nordlund	Founder	no data	kr25.00k	0.91% SEK 867.8k
Martin Andersson	Co-Founder & Chief Scientific Officer	15.3yrs	sin datos	0.39% SEK 372.3k
Kenth Hallberg	Founder & Director of Structural Chemistry	no data	sin datos	sin datos
Mathias Skalmstad	Chief Financial Officer	2.8yrs	sin datos	0.10% SEK 97.9k
Anne-Marie Wenthzel	Chief Business Officer	no data	sin datos	0.26% SEK 248.9k

2.8yrs

Permanencia media

52yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de SPRINT se considera experimentado (2.7 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Svein Mathisen	Independent Director	4.3yrs	kr140.00k	0.064% SEK 61.2k
Bjorn Sjostrand	Independent Chairman of the Board	3.3yrs	kr279.00k	1.26% SEK 1.2m
Lewis Cantley	Member of Scientific Advisory Board	no data	sin datos	sin datos
Rune Nordlander	Director	14.3yrs	kr140.00k	15.13% SEK 14.4m
Fredrik Lehmann	Independent Director	5yrs	kr140.00k	0.072% SEK 68.0k
Robert Devita	Member of Scientific Advisory Board	no data	sin datos	sin datos
Gunilla Enblad	Member of Scientific Advisory Board	no data	sin datos	sin datos
Karen From	Independent Director	less than a year	sin datos	sin datos

4.3yrs

Permanencia media

60.5yo

Promedio de edad

Junta con experiencia: La junta directiva de SPRINT se considera experimentada (4.3 años de antigüedad promedio).

Sprint Bioscience Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

High number of new and inexperienced directors

Director recently bought kr336k worth of stock

Sprint Bioscience AB (publ) Appoints Erik Kinnman as New CEO in Place of Charlotte Leife

Recent updates

Full year 2023 earnings released: kr0.006 loss per share (vs kr1.43 loss in FY 2022)

Third quarter 2023 earnings released: EPS: kr0.41 (vs kr0.33 loss in 3Q 2022)

Second quarter 2023 earnings released: kr0.17 loss per share (vs kr0.45 loss in 2Q 2022)

Estimating The Fair Value Of Sprint Bioscience AB (publ) (STO:SPRINT)

Now 23% undervalued after recent price drop

Now 21% undervalued after recent price drop

A Look At The Intrinsic Value Of Sprint Bioscience AB (publ) (STO:SPRINT)

Full year 2022 earnings released: kr1.43 loss per share (vs kr0.85 loss in FY 2021)

Price target decreased to kr3.30

Third quarter 2022 earnings released: kr0.33 loss per share (vs kr0.54 profit in 3Q 2021)

Second quarter 2022 earnings released: kr0.45 loss per share (vs kr0.60 loss in 2Q 2021)

First quarter 2022 earnings: EPS misses analyst expectations

Sprint Bioscience Launches NIMA at BIO International

Forecast to breakeven in 2023

High number of new and inexperienced directors

Full year 2021 earnings: EPS misses analyst expectations

Full year 2021 earnings: EPS exceeds analyst expectations

Third quarter 2021 earnings released: EPS kr0.54 (vs kr0.36 loss in 3Q 2020)

Director recently bought kr336k worth of stock

Sprint Bioscience AB (publ) Adds New Cancer Drug Program to its Project Portfolio

Second quarter 2021 earnings released: kr0.60 loss per share (vs kr1.01 loss in 2Q 2020)

First quarter 2021 earnings released: kr0.65 loss per share (vs kr0.79 loss in 1Q 2020)

Sprint Bioscience AB (publ) announced that it has received SEK 20.713701 million in funding

Interim Chief Executive Officer Charlotte Leife has left the company

Sprint Bioscience AB (publ) Appoints Erik Kinnman as New CEO in Place of Charlotte Leife

Revenue and earnings beat expectations

New 90-day low: kr6.52

Full year 2020 earnings released: kr2.02 loss per share (vs kr1.92 loss in FY 2019)

New 90-day low: kr7.10

Is Sprint Bioscience (STO:SPRINT) In A Good Position To Deliver On Growth Plans?

Third quarter 2020 earnings released: kr0.36 loss per share

CEO

Permanencia

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad